Skip to Content
Søk Menu
6.-10. DESEMBER 2022

Følg med når vi dekker SABCS 2022 | San Antonio Breast Cancer Symposium

MEDtalks fra SABCS 2020

SABCS2020: Ældre patienter med brystcancer bør behandles efter guidelines

/ Tove Filtenborg Tvedskov
BrystkreftSABCS20 Play the Video

SABCS2020: Robust survival outcome in HER2 positive metastatic breast cancer

/ Shanu Modi
BrystkreftSABCS20 Play the Video

SABCS2020: Trastuzumab Deruxtecan Continues to Demonstrate Durable Responses in HER2 Positive Metastatic Breast Cancer

/ Fabrice André
BrystkreftSABCS20 Play the Video

SABCS2020: Chemo-immune therapy as a first-line treatment of patients with metastatic triple-negative breast cancer

/ Hope S. Rugo
BrystkreftSABCS20 Play the Video

Har du en idé til en artikkel?

Send et forslag til redaksjonen

Send mail til redaksjonen

Onkologi / Hematologi • Nr. 5 • 2021

  • ASCO highlights
  • Brystkreft – resultater fra radiologisk re-granskning av intervallkreft
  • EHA highlights
  • Legemiddelresistens ved kronisk lymfatisk leukemi
Få tilgang

Mer fra SABCS2020

SABCS20: Circulating tumor cells can predict response in metastatic breast cancer

/ BestPractice Nordic
BrystkreftSABCS20

SABCS20: Trastuzumab deruxtecan is a promising new treatment for HER2 positive metastatic breast cancer

/ BestPractice Nordic
BrystkreftSABCS20

SABCS20: Abemacitib continues to show promising results in early breast cancer

/ BestPractice Nordic
BrystkreftSABCS20

SABCS20: Positive results of pembrolizumab in 1L for triple negative breast cancer regardless of chemotherapy partner

/ BestPractice Nordic
BrystkreftSABCS20

SABCS20: Postmenopausal women with early breast cancer and low risk score could skip adjuvant chemotherapy

/ BestPractice Nordic
BrystkreftSABCS20

SABCS2019

SABCS 2019: Et av de mest lovende medikamentene mot brystkreft

/ Henrik Lindman
BrystkreftSABCS19 Play the Video
Back to top